Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.

Abstract

Purpose: To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.

Methods: Case report.

Results: A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.

Conclusion: Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.